INNT - Innovate Biopharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Innovate Biopharmaceuticals, Inc.

8480 Honeycutt Road
Suite 120
Raleigh, NC 27615
United States
919-275-1933
http://www.innovatebiopharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. Sandeep Laumas M.D.CEO & Exec. Chairman687.5kN/A1969
Mr. Jay P. Madan M.S.Founder, Pres, Chief Bus. Officer & Director688.08kN/A1966
Dr. Christopher P. PriorConsultant605kN/A1953
Dr. June S. AlmenoffConsultant555.46kN/A1957
Mr. Edward J. SitarChief Financial & Accounting OfficerN/AN/A1963
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

Corporate Governance

Innovate Biopharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.